Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports

Novartis AG is reportedly nearing an acquisition of U.S. biotech Avidity Biosciences for more than $70 per share, with an announcement potentially imminent, according to Bloomberg News. This potential deal underscores Novartis's aggressive strategy to bolster its drug pipeline and drive future growth, following recent acquisitions in 2025 such as Tourmaline Bio for $1.4 billion and Regulus Therapeutics for up to $1.7 billion.

Analysis

Novartis AG is reportedly nearing an acquisition of U.S. biotech Avidity Biosciences for over $70 per share, with an announcement potentially imminent, according to Bloomberg News. This development indicates a significant premium for Avidity shareholders, reflecting the perceived value of its assets. The lack of immediate comment from both companies suggests ongoing sensitive negotiations.

This potential acquisition aligns with Novartis's stated strategy to aggressively bolster its drug pipeline and drive future growth through M&A in 2025. It follows two other notable acquisitions this year: Tourmaline Bio for $1.4 billion on a fully diluted basis and Regulus Therapeutics for up to $1.7 billion. These deals collectively demonstrate a clear focus on expanding therapeutic areas and intellectual property.

The series of strategic acquisitions reflects an optimistic outlook for Novartis's long-term growth trajectory, as evidenced by the "strongly positive" general sentiment and a 0.7 sentiment score for NVS. The substantial premium offered for Avidity Biosciences, indicated by its 0.9 sentiment score, highlights the perceived value of its pipeline. This aggressive inorganic growth strategy aims to secure future revenue streams and market position.

Key Decisions for Investors

• Investors should closely monitor the official confirmation and detailed terms of the Novartis-Avidity Biosciences acquisition, as this will clarify the strategic fit and financial implications.
• Evaluate Novartis's increased M&A activity in 2025, including the $1.4 billion Tourmaline Bio and up to $1.7 billion Regulus Therapeutics deals, for potential pipeline synergies and integration challenges.
• For current Avidity Biosciences shareholders, assess the reported acquisition price of over $70 per share against their cost basis for potential realization of significant premium.